The challenge of curbing aminoglycoside resistance: can antimicrobial stewardship programs play a critical role?

References

• Gilbert DN. Aminoglycosides. In: Mandell GL, Bennett JE, Dolin R, Eds. Principles and practice of infectious diseases. 6th ed. New York: Churchill Livingstone; 2005. p. 328.
   Google Scholar
• Haldorsen BC, Simonsen GS, Sundsfjord A, et al. Norwegian Study Group on aminoglycoside resistance. Increased prevalence of aminoglycoside resistance in clinical isolates of Escherichia coli and Klebsiella spp. in Norway is associated with the acquisition of AAC(3)-II and AAC(6ʹ)-Ib. Diagn Microbiol Infect Dis. 2014;78(1):66–69.
   PubMed Web of Science ®Google Scholar
• Labby KJ, Garneau-Tsodikova S. Strategies to overcome the action of aminoglycoside-modifying enzymes for treating resistant bacterial infections. Future Med Chem. 2013;5:1285–1309.
   PubMed Web of Science ®Google Scholar
• Dellit TH, Owens RC, McGowan JE, et al. Infectious Diseases Society of America and the Society For Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159–177.
   PubMed Web of Science ®Google Scholar
• MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev. 2005;18:638–656.
   PubMed Web of Science ®Google Scholar
• Owens RC Jr. Antimicrobial stewardship: concepts and strategies in the 21st century. Diagn Microbiol Infect Dis. 2008;61:110–128.
   PubMed Web of Science ®Google Scholar
• Vidal L, Gafter-Gvili A, Borok S, et al. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2007;60:247–257.
   PubMed Web of Science ®Google Scholar
• Lopez-Novoa JM, Quiros Y, Vicente L, et al. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int. 2011;79:33–45.
   PubMed Web of Science ®Google Scholar
• Pakyz AL, MacDougall C, Oinonen M, et al. Trends in antibacterial use in US academic health centers: 2002–2006. Arch Intern Med. 2008;168:2254–2260.
   PubMedGoogle Scholar
• Leibovici L, Vidal L, Paul M. Aminoglycoside drugs in clinical practice: an evidence-based approach. J Antimicrob Chemother. 2009;63:246–251.
   PubMed Web of Science ®Google Scholar
• Mueller EW, Boucher BA. The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered in critically ill surgical patients. Surg Infect. 2009;10:563–570.
   PubMed Web of Science ®Google Scholar
• Gerding DN. Antimicrobial cycling: lessons learned from the aminoglycoside experience. Infect Control Hosp Epidemiol. 2000;21:S12–7.
   PubMed Web of Science ®Google Scholar
• Brown EM, Nathwani D. Antibiotic cycling or rotation: a systematic review of the evidence of efficacy. J Antimicrob Chemother. 2005;55:6–9.
   PubMed Web of Science ®Google Scholar
• Bennett KM, Scarborough JE, Sharpe M, et al. Implementation of antibiotic rotation protocol improves antibiotic susceptibility profile in a surgical intensive care unit. J Trauma. 2007;63:307–311.
   PubMedGoogle Scholar
• Gerding DN, Larson TA. Aminoglycoside resistance in gram-negative bacilli during increased amikacin use. Comparison of experience in 14 United States hospitals with experience in the Minneapolis Veterans Administration Medical Center. Am J Med. 1985;79:1–7.
   PubMed Web of Science ®Google Scholar
• Young EJ, Sewell CM, Koza MA, et al. Antibiotic resistance patterns during aminoglycoside restriction. Am J Med Sci. 1985;290:223–227.
   PubMed Web of Science ®Google Scholar
• Saavedra S, Vera D, Ramírez-Ronda CH. Susceptibility of aerobic gram-negative bacilli to aminoglycosides. Effects of 45 months of amikacin as first-line aminoglycoside therapy. Am J Med. 1986;80:65–70.
   PubMed Web of Science ®Google Scholar
• Betts RF, Valenti WM, Chapman SW, et al. Five-year surveillance of aminoglycoside usage in a university hospital. Ann Intern Med. 1984;100:219–222.
   PubMed Web of Science ®Google Scholar
• Berk SL, Alvarez S, Ortega G, et al. Clinical and microbiologic consequences of amikacin use during a 42-month period. Arch Intern Med. 1986;146:538–541.
   PubMed Web of Science ®Google Scholar
• Francetić I, Smilja K, Mirjana H, et al. Impact of aminoglycoside cycling in six tertiary intensive care units – prospective longitudinal interventional study. Croat Med J. 2008;49:207–214.
   PubMed Web of Science ®Google Scholar
• Friedland IR, Funk E, Khoosal M, et al. Increased resistance to amikacin in a neonatal unit following intensive amikacin usage. Antimicrob Agents Chemother. 1992;36:1596–1600.
   PubMed Web of Science ®Google Scholar
• Bosso JA, Haines ML, Gomez J. Stable susceptibility to aminoglycosides in an age of low level, institutional use. Infect Dis Ther. 2013;2:209–215.
   PubMedGoogle Scholar
• Yong MK, Buising KL, Cheng AC, et al. Improved susceptibility of Gram-negative bacteria in an intensive care unit following implementation of a computerized antibiotic decision support system. J Antimicrob Chemother. 2010;65:1062–1069.
   PubMed Web of Science ®Google Scholar
• Zhang ZG, Chen F, Ou Y. Impact of an antimicrobial stewardship programme on antibiotic usage and resistance in a tertiary hospital in China. J Clin Pharm Ther. 2017. DOI:10.1111/jcpt.12544.
   Web of Science ®Google Scholar
• Hou D, Wang Q, Jiang C, et al. Evaluation of the short-term effects of antimicrobial stewardship in the intensive care unit at a tertiary hospital in China. PLoSOne. 2014;9:e101447.
   PubMed Web of Science ®Google Scholar
• Niwa T, Shinoda Y, Suzuki A, et al. Outcome measurement of extensive implementation of antimicrobial stewardship in patients receiving intravenous antibiotics in a Japanese university hospital. Int J Clin Pract. 2012;66:999–1008.
   PubMed Web of Science ®Google Scholar
• Zou YM, Ma Y, Liu JH, et al. Trends and correlation of antibacterial usage and bacterial resistance: time series analysis for antibacterial stewardship in a Chinese teaching hospital (2009-2013). Eur J Clin Microbiol Infect Dis. 2015;34:795–803.
   PubMed Web of Science ®Google Scholar
• Timbrook TT, Hurst JM, Bosso JA. Impact of an antimicrobial stewardship program on antimicrobial utilization, bacterial susceptibilities, and financial expenditures at an academic medical center. Hosp Pharm. 2016;51:703–711.
   PubMedGoogle Scholar
• Slain D, Sarwari AR, Petros KO, et al. Impact of a multimodal antimicrobial stewardship program on pseudomonas aeruginosa susceptibility and antimicrobial use in the intensive care unit setting. Crit Care Res Pract. 2011;416426. DOI:10.1155/2011/416426.
   PubMedGoogle Scholar
• Ababneh M, Harpe S, Oinonen M, et al. Trends in aminoglycoside use and gentamicin-resistant gram-negative clinical isolates in US academic medical centers: implications for antimicrobial stewardship. Infect Control Hosp Epidemiol. 2012;33:594–601.10.1086/665724.
   PubMed Web of Science ®Google Scholar
• Lortholary O, Tod M, Cohen Y, et al. Aminoglycosides. Med Clin North Am. 1995;79:761–787.
   PubMed Web of Science ®Google Scholar
• Paul M, Dickstein Y, Schlesinger A, et al. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database Syst Rev. 2013;29:CD003038. DOI:10.1002/14651858.CD003038.pub2.
   Web of Science ®Google Scholar
• Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev. 2012;25:450–470.
   PubMed Web of Science ®Google Scholar
• May AK. An argument for the use of aminoglycosides in the empiric treatment of ventilator-associated pneumonia. Surg Infect (Larchmt). 2016;17(3):329–333.
   PubMed Web of Science ®Google Scholar
• Boucher HW, Talbot GH, Benjamin DK Jr, et al. 10 x ‘20 progress–development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis. 2013;56:1685–1694.
   PubMed Web of Science ®Google Scholar
• Endimiani A, Paterson DL. Optimizing therapy for infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases. Semin Respir Crit Care Med. 2007;28:646–655.
   PubMed Web of Science ®Google Scholar
• Kasiakou SK, Lawrence KR, Choulis N, et al. Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters. Drugs. 2005;65:2499–2511.
   PubMed Web of Science ®Google Scholar
• Dubé J, Caillon C, Jacqueline D, et al. The optimal aminoglycoside and its dosage for the treatment of severe Enterococcus faecalis infection. An experimental study in the rabbit endocarditis model. Eur J Clin Microbiol Infect Dis. 2012;31:2545–2547.
   PubMed Web of Science ®Google Scholar
• Drusano GL, Louie A. Optimization of aminoglycoside therapy. Antimicrob Agents Chemother. 2011;55:2528–2531. DOI:10.1128/AAC.01314-10.
   PubMed Web of Science ®Google Scholar
• Udy AA, Roberts JA, Boots RJ, et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49:1–16.
   PubMed Web of Science ®Google Scholar
• Rea RS, Capitano B, Bies R, et al. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit. 2008;30:674–681.
   PubMed Web of Science ®Google Scholar
• Stankowicz MS, Ibrahim J, Brown DL. Once-daily aminoglycoside dosing: an update on current literature. Am J Health Syst Pharm. 2015;72:1357–1364.
   PubMed Web of Science ®Google Scholar
• Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in Gram-negative pneumonia. Am J Med. 1984;77:657–662.
   PubMed Web of Science ®Google Scholar
• Torfoss D, Hoiby EA, Tangen JM, et al. Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial. J Antimicrob Chemother. 2007;59:711–717.
   PubMed Web of Science ®Google Scholar
• Swan SK. Aminoglycoside nephrotoxicity. Semin Nephrol. 1997;17:27–33.
   PubMed Web of Science ®Google Scholar
• Croes S, Koop AH, van Gils SA, et al. Nephrotoxicity and ototoxicity of aminoglycosides, mathematically modelled for modelling-supported therapeutic drug monitoring. Eur J Pharm Sci. 2012;45;23:90–100.
   Web of Science ®Google Scholar
• Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39:650–655.
   PubMed Web of Science ®Google Scholar
• Sánchez-Alcaraz A, Vargas A, Quintana MB, et al. Therapeutic drug monitoring of tobramycin: once-daily versus twice-daily dosage schedules. J Clin Pharm Ther. 1998;23:367–373.
   PubMed Web of Science ®Google Scholar
• Barclay ML, Kirkpatrick CM, Begg EJ. Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet. 1999;36:89–98.
   PubMed Web of Science ®Google Scholar
• Smits A, Kulo A, van den Anker J, et al. The amikacin research program: a stepwise approach to validate dosing regimens in neonates. Expert Opin Drug Metab Toxicol. 2017;13:157–166.
   PubMed Web of Science ®Google Scholar
• Abdel-Hady E, El Hamamsy M, Hedaya M, et al. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis. J Clin Pharm Ther. 2011;36:45–52.
   PubMed Web of Science ®Google Scholar
• Nezic L, Derungs A, Bruggisser M, et al. Therapeutic drug monitoring of once daily aminoglycoside dosing: comparison of two methods and investigation of the optimal blood sampling strategy. Eur J Clin Pharmacol. 2014 Jul; 70(7):829–837. DOI:10.1007/s00228-014-1680-3.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Norris R, Paterson DL, et al. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol. 2012;73:27–36.
   PubMed Web of Science ®Google Scholar
• Drusano GL, Ambrose PG, Bhavnani SM, et al. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis. 2007;45:753–760.
   PubMed Web of Science ®Google Scholar
• Barras MA, Serisier D, Hennig S, et al. Bayesian Estimation of tobramycin exposure in patients with cystic fibrosis. Antimicrob Agents Chemother. 2016;60:6698–6702.
   PubMed Web of Science ®Google Scholar
• Singhal N, Kumar M, Kanaujia PK, et al. MALDI-TOF mass spectrometry: an emerging technology for microbial identification and diagnosis. Front Microbiol. 2015;6:791.
   PubMed Web of Science ®Google Scholar
• Clinical laboratory testing and in vitro diagnostic test systems — Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices — Part 1: Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. https://www.iso.org/standard/41630.html
   Google Scholar